Latest filings (excl ownership)
8-K
Emergent Biosolutions Reports First Quarter 2024 Financial Results
1 May 24
8-K
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
1 May 24
8-K
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
30 Apr 24
8-K
Departure of Directors or Certain Officers
26 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
6 Mar 24
8-K
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
21 Feb 24
8-K
Other Events
11 Jan 24
8-K
Regulation FD Disclosure
9 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Dec 23
S-8
Registration of securities for employees
11 Dec 23
10-Q
2023 Q3
Quarterly report
11 Dec 23
10-K/A
2022 FY
Annual report (amended)
11 Dec 23
8-K
Other Events
28 Nov 23
8-K
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
24 Nov 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Nov 23
NT 10-Q
Notice of late quarterly filing
9 Nov 23
8-K
Emergent Biosolutions Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
A Statement on Emergent’s Camden Manufacturing Facility Regulatory Status
5 Oct 23
8-K
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
2 Oct 23
8-K
Other Events
30 Aug 23
8-K
Emergent’s Statement Regarding the Passing of a Director of the Board
16 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Emergent Biosolutions Reports Financial Results for Second Quarter 2023
8 Aug 23
8-K
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
8 Aug 23
8-K
Other Events
31 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jul 23
8-K
Regulation FD Disclosure
21 Jul 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
S-8
Registration of securities for employees
5 Jun 23
8-K
Departure of Directors or Certain Officers
31 May 23
8-K
Entry into a Material Definitive Agreement
30 May 23
424B5
Prospectus supplement for primary offering
18 May 23
8-K
Emergent’s Statement Regarding its Amended Credit Agreement
17 May 23
8-K
Completion of Acquisition or Disposition of Assets
15 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Emergent Biosolutions Reports Financial Results for First Quarter 2023
9 May 23
Latest ownership filings
4
Coleen Glessner
9 Apr 24
4
William Hartzel
9 Apr 24
4
JOSEPH C PAPA
15 Mar 24
4
Paul Anthony Williams
15 Mar 24
4
Coleen Glessner
15 Mar 24
4
Jennifer Lynne Fox
15 Mar 24
4
RICHARD S LINDAHL
15 Mar 24
4
William Hartzel
15 Mar 24
4
William Hartzel
7 Mar 24
4
Coleen Glessner
4 Mar 24
4
Paul Anthony Williams
4 Mar 24
4
RICHARD S LINDAHL
4 Mar 24
4
Jennifer Lynne Fox
4 Mar 24
3
JOSEPH C PAPA
29 Feb 24
4
Paul Anthony Williams
27 Feb 24
4
Jennifer Lynne Fox
27 Feb 24
4
RICHARD S LINDAHL
27 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
9 Feb 24
SC 13G/A
STATE STREET CORP
23 Jan 24
SC 13G/A
BlackRock Inc.
19 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
18 Jan 24
4
Jennifer Lynne Fox
14 Nov 23
4
Paul Anthony Williams
14 Nov 23
4
William Hartzel
14 Nov 23
SC 13G/A
BlackRock Inc.
7 Nov 23
SC 13G/A
STATE STREET CORP
10 Oct 23
SC 13G/A
VANGUARD GROUP INC
10 Oct 23
4
Neal Franklin Fowler
5 Oct 23
4
Donald W DeGolyer
5 Oct 23
3
Neal Franklin Fowler
5 Oct 23
3
Donald W DeGolyer
5 Oct 23
SC 13G
MILLENNIUM MANAGEMENT LLC
7 Sep 23
SC 13G/A
BlackRock Inc.
7 Sep 23
3
William Hartzel
15 Aug 23
4
Paul Anthony Williams
24 Jul 23
4
Kathryn C Zoon
24 Jul 23
3
H HAYWOOD MILLER III
18 Jul 23
4
Paul Anthony Williams
13 Jun 23
4
Coleen Glessner
13 Jun 23